LACTB and infection: The MERINO trial has shown that mortality rates are lower with the use of carbapenems, rather than Beta-lactam beta-lactamase inhibitor (BL-BLI) combination for infections caused by Extended Spectrum Beta Lactamase producing bacteria, though the clinical and bacteriological resolution of infections was not different between the two groups (12).